Biosimilar agents are similar but non-identical versions of existing biological drugs and may be authorized for use once the patent on the reference product has expired. Based on a recent market forecast of IMS, biosimilars are forecasted to deliver total savings of as much as $110 billion to health systems across Europe and the U.S. through 2020.
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, conducted May 21-25, 2-16, in Washington, DC, industry professionals convened to delve into the topic “Value, Affordability, and Patient Centeredness: Can We Have it All?” UBC’s Value Demonstration experts joined the conversation with five abstracts highlighting some of their recentresearch.
A recent report from the Pharmacovigilance and Risk Assessment Committee (PRAC) found that in the 200+ study protocols reviewed, nearly half suffered from study design flaws. Don’t let methodological issues stall approval of your next Post-Authorisation Safety Study (PASS).
I work on a study unlike any other here at UBC. Yet, the patients enrolled in this study all have very similar characteristics: they have long fur … wet noses … and wagging tails. These patients are golden retrievers.
Time and Motion (T&M) studies are observational studies designed to quantify efficiency-related outcomes associated with: